🏥┃HbO2 Therapeutics
Introduction
Hemoglobin Oxygen Therapeutics LLC (HbO2 Therapeutics) is a pioneering company specializing in the development of hemoglobin-based oxygen carriers (HBOCs) for both human and veterinary applications. These therapies, when administered intravenously, enhance the oxygen-carrying capacity of the blood. The company offers two primary products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use and Oxyglobin® [hemoglobin glutamer - 200 (bovine)] for veterinary use.
History
In 2001, Hemopure received approval in South Africa for treating acute anemia in adult surgical patients, helping to eliminate, delay, or reduce the need for allogeneic red blood cells. By 2010, Hemopure was also approved in Russia for treating acute anemia of any cause.
Though Hemopure is considered an investigational drug in the U.S. and is not yet FDA-approved for human use, it is available through clinical trials or expanded access (often referred to as compassionate use). Under the FDA’s Expanded Access Program (EAP), Hemopure has been widely used in the U.S. to treat patients with severe, life-threatening anemia when blood transfusions are not possible and all other treatments have been exhausted. This can occur due to the unavailability of compatible blood, contraindications for blood transfusion, or religious refusal of transfusions.
Oxyglobin, the veterinary equivalent, has been approved in the U.S. and Europe for over 20 years. It is used to treat canine anemia by boosting plasma and total hemoglobin levels, thereby increasing arterial oxygen content. It was the first veterinary therapy of its kind to gain approval, with over 240,000 units sold and approximately 30 animal species treated off-label.
Both Hemopure and Oxyglobin reflect over 25 years of research and development, including 22 clinical trials and more than 250 preclinical studies. Through continued scientific innovation and collaboration, HbO2 Therapeutics is committed to advancing these products and exploring new applications to address unmet medical needs.
Links
Last updated
